Dianthus Therapeutics’ (DNTH) “Buy” Rating Reiterated at HC Wainwright

Dianthus Therapeutics (NASDAQ:DNTH)‘s stock had its “buy” rating reiterated by stock analysts at HC Wainwright in a report released on Monday, Benzinga reports. They currently have a $40.00 price objective on the stock. HC Wainwright’s price target would indicate a potential upside of 50.77% from the stock’s current price.

Several other equities analysts also recently weighed in on the stock. Lifesci Capital upgraded shares of Dianthus Therapeutics to a “strong-buy” rating in a report on Tuesday, June 11th. Cantor Fitzgerald started coverage on shares of Dianthus Therapeutics in a research note on Thursday, June 27th. They issued an “overweight” rating on the stock. Robert W. Baird initiated coverage on shares of Dianthus Therapeutics in a report on Friday, July 26th. They set an “outperform” rating and a $58.00 target price for the company. Baird R W raised shares of Dianthus Therapeutics to a “strong-buy” rating in a report on Friday, July 26th. Finally, Wedbush cut their price target on Dianthus Therapeutics from $38.00 to $36.00 and set an “outperform” rating on the stock in a research report on Friday. Eight research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus price target of $44.71.

Dianthus Therapeutics Trading Down 3.5 %

Shares of NASDAQ:DNTH traded down $0.97 on Monday, hitting $26.53. 73,923 shares of the company were exchanged, compared to its average volume of 193,577. The firm has a market capitalization of $778.63 million, a P/E ratio of -4.55 and a beta of 1.89. Dianthus Therapeutics has a 1-year low of $6.58 and a 1-year high of $33.77. The stock’s 50 day moving average price is $26.34 and its 200 day moving average price is $25.10.

Dianthus Therapeutics (NASDAQ:DNTH) last issued its earnings results on Thursday, August 8th. The company reported ($0.51) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.50) by ($0.01). The company had revenue of $1.86 million during the quarter, compared to the consensus estimate of $0.63 million. On average, equities analysts predict that Dianthus Therapeutics will post -2.18 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of DNTH. Bain Capital Life Sciences Investors LLC purchased a new position in shares of Dianthus Therapeutics in the 1st quarter valued at about $89,761,000. RA Capital Management L.P. acquired a new stake in Dianthus Therapeutics in the first quarter valued at approximately $69,990,000. Vanguard Group Inc. increased its position in shares of Dianthus Therapeutics by 250.0% in the first quarter. Vanguard Group Inc. now owns 537,828 shares of the company’s stock valued at $16,135,000 after buying an additional 384,182 shares in the last quarter. Janus Henderson Group PLC acquired a new position in shares of Dianthus Therapeutics during the 1st quarter worth approximately $11,251,000. Finally, Vestal Point Capital LP purchased a new position in shares of Dianthus Therapeutics during the 4th quarter valued at approximately $1,404,000. Institutional investors and hedge funds own 47.53% of the company’s stock.

About Dianthus Therapeutics

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.